Innate Pharma (IPHA) Assets Average (2018 - 2025)
Innate Pharma's (IPHA) quarterly Assets Average came in at $89.1 million in Q4 2025, down 36.77% YoY from $140.9 million in Q4 2024, and down 20.4% on a QoQ basis from $111.9 million in Q2 2025.
Innate Pharma (IPHA) Assets Average (2018 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Assets Average data on file, last reported at $89.1 million in Q4 2025.
- Quarterly Assets Average fell 36.77% year-over-year to $89.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $89.1 million (down 36.77% YoY) and the FY2025 annual result came in at $95.8 million, down 37.6% from the prior year.
- Assets Average eased to $89.1 million in Q4 2025, from $111.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $343.6 million in Q2 2021 to a low of $89.1 million in Q4 2025.
- A 5-year average of $214.1 million and a median of $206.3 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average slumped 99.81% — and 2022, when it decreased 11.92%.
- Tracing IPHA's Assets Average over 5 years: stood at $313.3 million in 2021, then dropped by 19.8% to $251.3 million in 2022, then dropped by 19.37% to $202.6 million in 2023, then sank by 30.46% to $140.9 million in 2024, then plunged by 36.77% to $89.1 million in 2025.
- The last three Assets Average figures came in at $89.1 million (Q4 2025), $111.9 million (Q2 2025), and $140.9 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 89.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89.10 Mn |
| Jun 30, 2025 | 111.94 Mn |
| Dec 31, 2024 | 140.91 Mn |
| Jun 30, 2024 | 175.82 Mn |
| Dec 31, 2023 | 202.62 Mn |
| Jun 30, 2023 | 210.04 Mn |
| Dec 31, 2022 | 251.28 Mn |
| Jun 30, 2022 | 302.62 Mn |
| Dec 31, 2021 | 313.30 Mn |
| Jun 30, 2021 | 343.57 Mn |
| Dec 31, 2020 | 166.72 Bn |
| Jun 30, 2020 | 166.76 Bn |
| Dec 31, 2018 | 410.09 Mn |